Obio Technology closes Series B+ financing round

Obio Technology has completed the Series B+ round of financing totaling some 100 million yuan. This round is led by Golden Partners Capital, with participation from HRVC Capital and Efung Capital.

Obio Technology has completed the Series B+ round of financing totaling some 100 million yuan. This round is led by Golden Partners Capital, with participation from HRVC Capital and Efung Capital.

To date, Obio Technology has obtained three rounds of investment since its inception, and the total amount of financing has reached several hundred million yuan.

Obio Technology is a developer of gene therapy drugs designed to provide medical solutions for virus disease treatment. The company focuses on research and development of gene therapy drugs and provides and virus testing kits, enabling customers to obtain efficient medical treatment for virus and diseases.

In 2016, Obio Technology invested hundreds of millions yuan to carry out all-round strategic cooperation with GE Healthcare, and in the first quarter of 2017, it started to construct a one-time GMP-level recombinant virus production workshop. In March 2019, the GMP virus production platform jointly created by the two sides officially went into operation.

The platform can meet the volume of drug carriers required for the treatment of 150 patients in one production and can serve 2,000 patients a year. At present, the platform has cooperated with various gene therapy or cell therapy drug companies.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/06/07/obio-technology-closes-series-b-financing-round/.

Leave a Reply

Please Login to Comment